Pneumo Studien Darmstadt GmbH

Darmstadt 19 trials 3 recruiting

19 Registered trials

3 Currently recruiting

Organisation

Pneumo Studien Darmstadt GmbH

Location

Darmstadt, Germany

Identifier

ORG-100044589

Address

Grafenstrasse 13, 64283, Germany

Departments

-
4504: Pulmonology
N/A
NA
Not applicable
Pneumo Studien Darmstadt GmbH
Pneumologie
Pneumostudien
Pneumostudien Darmstadt
Pneumostudien Darmstadt GmbH
Studienzentrum

Clinical trials at this site (19)

Search interface

A Phase 2 Randomized, Double-blind Placebo-Controlled Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety and Efficacy of WIN378 … Recruiting

2025-521391-58-00 Asthma 4 2025-11-28
A study to investigate the effect of AZD6793 in participants with moderate to very severe chronic obstructive pulmonary disease Recruiting

2025-520473-40-00 Moderate to Very Severe Chronic Obstructive Pulmonary D 4 2025-09-29
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C… Recruiting

2023-507407-59-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-07-04
Study to assess whether Verekitug can improve the control of Chronic Obstructive Pulmonary Disease (COPD) Ended

2025-520488-42-00 Moderate-to-Severe Chronic Obstructive Pulmonary Diseas 4 2025-09-17
A dose finding study with an anti-TSLP antibody (GSK5784283) in adults aged 18 to 75 years of age with uncontrolled asthma. Ended

2024-518321-15-00 Asthma 4 2025-05-30
A Study to Assess the Effectiveness and Safety of Taplucainium Inhalation Powder (NOC-110) in Adults with Refractory or Unexplained Chronic … Ended

2024-515026-86-00 Refractory or Unexplained Chronic Cough 4 2024-12-18
A Randomized, Double Blind, Active-Controlled Study on Efficacy and Safety of TEV-56248 in Patients with Asthma Ended

2023-505435-12-00 Asthma 5 2024-06-04
REIMAGINE – Real-world EvaluatIon of Mepolizumab in severe Asthma achievinG on treatment clinIcal remissioN, a prospEctive study. Ended

2023-509026-21-00 severe asthma 6 2024-06-03
A Phase 3, 24-Week, Randomized, Efficacy and Safety Study with Openlabel Extension of BLU-5937 in Adult Participants with Refractory or Unex… Ended

2024-513462-19-00 Refractory Chronic Cough, Including Unexplained Chronic 5 2023-03-30
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dos… Ended

2023-506000-50-00 Adult Patients with Moderate-to-Severe Asthma Uncontrol 4 2024-09-26
"Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended

2023-505543-39-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-02-12
A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease Ended

2022-502234-70-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2023-07-14
Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended

2022-501063-41-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2023-04-20
Study to assess efficacy, safety, and tolerability of Tozorakimab in patients with symptomatic chronic obstructive pulmonary disease (COPD) … Ended

2023-503572-24-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2022-03-02
The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy Ended

2023-510174-13-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2021-06-17
The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD) Ended

2023-510175-60-00 Chronic obstructive pulmonary disease (COPD) and Chron 5 2021-06-16
Non-inferiority study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosin… Ended

2023-510230-84-00 Severe asthma with an eosinophilic phenotype 5 2021-05-28
A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with S… Ended

2023-505786-88-00 Severe and inadequately controlled asthma 5 2021-04-25
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent Exace… Ended

2022-503050-39-00 Moderate to Very Severe Chronic Obstructive Pulmonary D 5 2019-11-12